**Author details**

In this study, for an equipment activity extending over a period of 7 years, the cost of acquisition and maintenance cost represent, respectively, 11.4% and 5.0% of

But when the activity of the same equipment is done over a period of 2 years, the cost of acquisition and maintenance cost represent, respectively, 31.0% and 3.9% of

Added to this, for the same annual rate, the minimum unit test cost is € 3.9 for a 7-year activity cycle, whereas it costs € 5 if the activity cycle is reduced to

Therefore, it should be noted that when operating conditions remain the same, amortization of equipment carried on shorter lead times significantly increases the

Even though this example only concerns electrophoresis capillary equipment, extrapolating conclusions on agarose gel equipment is possible for the following reasons: installation, operation, and maintenance are less demanding than for cap-

While sub-Saharan Africa is the most affected region in the world for sickle cell

At its 60th session held in Malabo from 30 August to 3 September 2010, the WHO was already raising the option of a strategy for its African region. Nine years

The management improvement of this pathology solicits several challenges, including the one concerning the technical platform necessary for diagnosis. The costs of acquiring and operating equipment often require significant fundraising, which is often lacking. The missing financial means are often one of the first

The study mentioned above proves that it is possible to optimize the available resources, however modest they may be, in order to obtain good and lasting results. In the case of biomedical equipment, it is sufficient to involve the right people to achieve the expected results. Policymakers in sub-Saharan African countries must therefore integrate the skills of biomedical engineers into the design and start-up of medical projects so that they, in turn, contribute effectively to improve the quality

the total life cycle cost.

the total life cycle cost.

cost of the test at the expense of patients.

*Human Blood Group Systems and Haemoglobinopathies*

disease, research and care are relatively slow.

obstacles to the launching of the relevant programs.

after the effects are hardly noticeable.

of medical care populations.

**196**

2 years [37].

illary technology.

Vincent Mulunda-a-Mulunda<sup>1</sup> \*, Pierre Kouam<sup>2</sup> and Taty Oke Ingwen<sup>3</sup>

1 Institut Supérieur de Techniques Appliquées (ISTA), Kinshasa, Democratic Republic of Congo

2 Groupe Hospitalier Nord Essonne, Lonjumeau, France

3 Wagenia Sarl, Kinshasa, Democratic Republic of Congo

\*Address all correspondence to: vp\_amulunda@yahoo.fr

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
